



Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without Type 2 Diabetes

Vincenzo Maria Monda · Sandro Gentile · Francesca Porcellati · Ersilia Satta · Alessandro Fucili · Marcello Monesi · Felice Strollo

Received: July 28, 2022 / Accepted: August 24, 2022
© The Author(s) 2022

ABSTRACT

After examining the complex interplay between heart failure (HF) in its various clinical forms, metabolic disorders like nonalcoholic fatty liver disease (NAFLD), and obstructive sleep apnea (OSA) syndrome, in this mini-review we described possible favorable effects of sodium–glucose cotransporter 2 inhibitors (SGLT2is) on HF with preserved (i.e., $\geq 50\%$) ejection fraction (HFpEF) through enhanced cardiorenal function and

visceral-subcutaneous body fat redistribution. In greater detail, on the basis of pathophysiological mechanisms underlying OSA onset and the direct positive SGLT2i effect on renal function benefiting chronic kidney disease, we emphasized the promising role of SGLT2is in prevention, rehabilitation, and treatment of patients with OSA regardless of coexisting type 2 diabetes (T2DM). Indeed, SGLT2is enhance lipolysis and fatty acid beta-oxidation. These phenomena might prevent OSA by reducing the size of visceral and subcutaneous

V. M. Monda
Diabetes Unit “Santissima Annunziata” Hospital
Cento, Ferrara, Italy
e-mail: v.monda@ausl.fe.it

S. Gentile (✉)
Department of Precision Medicine, Campania
University “Luigi Vanvitelli”, Naples, Italy
e-mail: s.gentile1949@gmail.com

S. Gentile
Nefrocenter Research Network, Cava dé Tirreni, Italy

F. Porcellati
Section of Internal Medicine, Endocrinology and
Metabolism, Department of Medicine, Perugia
University School of Medicine, Perugia, Italy
e-mail: f.porcellati.fp@gmail.com

E. Satta
Polyspecialistic Nephrologic Center CNP Srl, Fratta
Maggiore, Italy

E. Satta
Nefrocenter Research Network, Cava dé Tirreni, Italy
e-mail: e.satta@nefrocenter.it

A. Fucili
Cardiovascular Research Center, Ferrara University,
Ferrara, Italy
e-mail: fucilialessandro@gmail.com

M. Monesi
Diabetes Unit “Sant’Anna” Hospital Ferrara, Ferrara,
Italy
e-mail: m.monesi@ausl.fe.it

F. Strollo
Department of Endocrinology and Diabetes, IRCCS
San Raffaele Pisana, Rome, Italy
e-mail: felix.strollo@gmail.com

adipose tissue and, as proven in humans and animals with T2DM, counteract NAFLD onset and progression. The aforementioned mechanisms may represent an additional SGLT2i cardioprotective effect in terms of HFpEF prevention in patients with OSA, whose NAFLD prevalence is estimated to be over 50%.

Keywords: Heart failure; Preserved ejection fraction; Obstructive sleep apnea; SGLT2is; T2DM; NAFLD; Cardiorenal protection; Rehabilitation

Key Summary Points

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately 40–50% of incident HF, and is associated primarily with hypertension, coronary heart disease, chronic kidney disease, type 2 diabetes mellitus (T2DM), and nonalcoholic fatty liver disease (NAFLD).

The prevalence of NAFLD is up to 50% in patients with HFpEF.

Moreover, obstructive sleep apnea (OSA) may be a significant risk factor for HFpEF.

The putative mechanism underlying the association between OSA and HFpEF seems to be the intermittent hypoxia-induced autonomic nervous system stimulation mediated by oxidative and endoplasmic reticulum stress.

Sodium–glucose cotransporter 2 inhibitors (SGLT2is) proved effective in reducing cardiovascular events in patients with HFpEF and improving renal function independently of T2DM.

SGLT2is also proved active against NAFLD in T2DM.

Considering the close association between OSA and HFpEF, SGLT2is might also be promising for OSA prevention, treatment, and rehabilitation regardless of coexisting T2DM, as well as for the often-associated NAFLD when T2DM is present.

Heart failure (HF) encompasses a broad spectrum of disorders involving myocardial dysfunction with typical signs and symptoms. The European Society of Cardiology (ESC) guidelines include echocardiographic parameters, i.e., left ventricular ejection fraction (EF), for subclassification of this complex clinical entity: heart failure with reduced EF (HFrEF; EF < 40%), mid-range EF (HFmrEF; EF 41–49%), and preserved EF (HFpEF \geq 50%) [1].

HFpEF accounts for approximately 40–50% of incident HF overall [2], and is associated with many cardiovascular risk factors, like arterial hypertension (AH) [2] and coronary heart disease (CAD) [3]. Other comorbidities are associated with HFpEF. They include obesity, atrial fibrillation (AF), metabolic syndrome, diabetes, chronic obstructive pulmonary disease, chronic kidney disease (CKD), and transthyretin-related amyloidosis [4–6]. Other parameters for the diagnosis of HFpEF are evidence of either diastolic dysfunction or structural heart disease, signs or symptoms of heart failure, and elevated natriuretic peptides [1].

According to a recent hypothesis, obstructive sleep apnea (OSA) may be a significant risk factor for HFpEF [7]. Frequent episodes of apnea characterize OSA during sleep due to upper airway obstructions, which might be either total (consisting of the cessation of respiratory flow for a period greater than 10 s) or partial (so-called hypopneas, consisting of a reduction of respiratory flow by more than 50% of normal) [8, 9].

The gold standard for diagnosing OSA involves simultaneous monitoring of sleep and

breathing, so-called polysomnography (PSG) [10], providing two clinically relevant indices: the apnea–hypopnea index (AHI; i.e., the mean number of episodes of apnea and hypopnea per hour of sleep) and the oxygen desaturation index (ODI; i.e., the mean number of oxygen desaturations of at least 3–4% below baseline per hour of sleep) [11].

The third edition of the International Classification of Sleep Disorders (ICSD-3) defines OSA as a PSG-determined obstructive respiratory disturbance index (RDI) ≥ 5 events per hour of sleep associated with the typical symptoms of OSA (e.g., unrefreshing sleep, daytime sleepiness, fatigue or insomnia, awakening with a gasping or choking sensation, loud snoring, or witnessed apneas), or an obstructive RDI ≥ 15 events for an hour of sleep (even in the absence of symptoms) [12]. Another index called RERAs (respiratory effort-related arousals) is also critical for the clinical evaluation of OSA [13, 14].

The diagnosis of sleep apnea/hypopnea syndrome (OSA syndrome, OSAS) refers to the association of OSA with utmost, unexplained daytime sleepiness or two or more of the following unexplained symptoms: sleep-time choking or gasping, recurrent awakenings, unrefreshing sleep, daytime fatigue, and impaired concentration [15, 16]. According to the so-called Chicago criteria [17], its severity is given by the AHI value as follows: absent (< 5), mild (5–14), moderate (15–29), and severe (≥ 30) [9].

A study on 252 patients with HF found an 86%, 86%, and 62% prevalence of sleep-disordered breathing (SDB) ($p = 0.001$) in those with HFrEF, HFmrEF, and HFpEF, respectively. OSA was present in 48% and central sleep apnea (CSA) in 22% of those patients. The prevalence of OSA among the three groups was 42%, 47%, and 49%, respectively ($p = 0.708$), while the prevalence of CSA among the three groups was 44%, 40%, and 13% ($p < 0.001$) [18]. So, the prevalence and severity of SDB in patients with HFrEF and HFmrEF were significantly higher than in those with HFpEF and were mainly related to the high prevalence of CSA. In contrast, OSA was more prevalent in HFpEF [18].

Another prospective, cross-sectional, case–control study on 25 patients with HFpEF

and 25 controls also showed a higher SDB prevalence in the former group (64% vs. 12%; odds ratio [OR] = 12.2, 95% confidence interval [CI] = 2.83–52.74; $p < 0.001$) [19]. AHI severity significantly correlated with diastolic dysfunction degree ($r = 0.67$; $p < 0.001$). Among patients with HFpEF and SDB (16/25), 13 had OSA, and only three had central sleep CSA, thus confirming the higher prevalence of OSA in patients with HFpEF [19].

The putative mechanism underlying the association between OSA and HFpEF seems to be the intermittent hypoxia-induced stimulation of the sympathetic nervous system and renin–angiotensin–aldosterone system (RAAS). The latter causes a systemic inflammatory state, mediated by tumor necrosis factor (TNF)-alpha and transforming growth factor (TGF) beta-1 [20], with oxidative stress and endoplasmic reticulum stress, mediated mainly by the activation of hypoxia-inducible factor 1 transcription factor [21].

Until recently, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and beta-blockers alleviating symptom burden and reducing mortality in patients with HFrEF did not prove equally effective in HFpEF [22–26]. The randomized, double-blind TOPCAT study, which aimed to determine the effect of spironolactone on mortality in patients with HFpEF, showed that it did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for HF [27]. In addition, despite being superior to enalapril against risks of death and hospitalization for patients with HFrEF in the PARADIGM trial [28], according to the following PARAGON-HF trial, the sacubitril–valsartan combination could not reduce the rate of either HF-related hospitalizations or cardiovascular death [29].

Initially, only statins were supposed to reduce HFpEF mortality [30]. Then, the randomized, double-blind placebo-controlled EMPEROR–Preserved trial clearly showed the glucose-lowering sodium–glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin to reduce the combined risk of cardiovascular death, HF-related hospitalization, and

emergency/urgent HF visits requiring intravenous treatment in such patients. This great achievement was independent of diabetes (432 patients on empagliflozin vs. 546 on placebo; hazard ratio, 0.77 [95% CI 0.67–0.87]; $p < 0.0001$) [31].

On the basis of pathophysiological mechanisms underlying OSA onset-related and renal SGLT2 effects, we already suggested SGLT2is as promising for prevention, rehabilitation, and treatment of patients with OSA regardless of coexisting diabetes. This approach would expand their indications beyond current ones, including glucose, lipids, uric acid, blood pressure, body weight control, and chronic HF, and kidney disease prevention [32]. This hypothesis finds further support in the previously mentioned EMPEROR-Preserved trial because of the close association between OSA and HFpEF [7, 33]. Indeed, OSA is associated with an increased risk of hospital admission for HFpEF [34]. In addition, taking into account that HFpEF is more frequent in women [35], it is noteworthy that HFpEF is significantly more frequent in patients with SDB [36].

Moreover, a clear benefit of SGLT2is has been recently proven in chronic kidney disease (CKD) in patients with and without diabetes, mediated by a direct improvement of renal function [37, 38] and by the ability to prevent the associated cardiovascular autonomic neuropathy from further self-sustaining kidney function impairment [39, 40], and by the ability to reduce the associated increased albumin urinary excretion [41].

The relationship between OSA and CKD is likely bidirectional [42], even in the early stage of the disease [43, 44]. So, considering that OSA is associated with accelerated loss of kidney function [45] and is a risk factor for incident end-stage renal disease [46], the proven benefit for CKD further supports the use of SGLT2is for patients with OSA independently of coexisting diabetes.

Further evidence of the favorable effect on OSA pathophysiology comes from the proven effect of SGLT2is on visceral and subcutaneous adipose tissue [47–49]. As shown in animal models of T2DM and metabolic syndrome, the latter depends on the increased lipolysis and

beta-oxidation of fatty acids [50–52] caused by a shift in energy substrates from carbohydrates to lipids [53]. SGLT2is proved active against liver steatosis in humans and animals with T2DM [54–58]. Canagliflozin, an SGLT2i, reduced epicardial fat accumulation [59], which is closely associated with coronary heart disease [60, 61].

Moreover, the lipolytic activity and the beneficial effects on nonalcoholic fatty liver disease (NAFLD) [62] may represent an additional SGLT2i cardioprotective mechanism in patients with OSA [63], who, in fact, often suffer from NAFLD [64, 65], obesity, and metabolic syndrome [66]. Indeed, some HFpEF phenotypes seem to be cardiac manifestations of NAFLD, thus supporting the novel concept of a pathophysiological continuum between NAFLD and HFpEF. Such a view is supported by multiple shared pathophysiological mechanisms that rely on increased systemic inflammation [67] and contribute to the associated endothelial dysfunction [67]. Indeed, NAFLD and nonalcoholic steatohepatitis (NASH) favor the accumulation of epicardial fat secreting proinflammatory adipocytokines, thus causing microvessel dysfunction and adjacent myocardium fibrosis. All the above leads to HFpEF and an increased risk of AF [68]. Also, a recent clinical prospective study on 181 patients followed as part of the University of Michigan HFpEF outpatient clinic reported a higher NAFLD prevalence (up to 50%) in patients with HFpEF than in those with HFrEF [69].

All the above further supports the hypothesis of cardiovascular and neurological (polysomnographic parameters) SGLT2i benefits in OSA independently of diabetes [32].

SGLT2is have also been supposed to elicit positive effects in patients with OSA through an intriguing yet controversial effect [70], i.e., hindered activation of leptin [71], whose levels are high in OSA [72, 73]. Indeed, in support of this hypothesis, a recent meta-analysis of ten randomized controlled trials showed that SGLT2is treatment was associated with decreased circulating leptin and increased adiponectin levels in patients with T2DM [74].

In conclusion, the putative favorable effect of SGLT2is in patients with OSA is likely due to the ability to reduce cardiovascular events in




Fig. 1 Putative mechanisms of the benefit of SGLT2is in patients with OSA with and without diabetes. *SGLT2is* sodium–glucose cotransporter 2 inhibitors, *CKD* chronic

kidney disease, *HFpEF* heart failure with preserved ejection fraction, *NAFLD* nonalcoholic liver disease, *NASH* non-alcoholic steatohepatitis

patients with HFpEF [31] and improve renal function independently of diabetes [37, 38]. OSA is an independent risk factor for cardiovascular and cerebrovascular events independently of diabetes [75, 76] and has a high prevalence especially in patients with obesity resistant to antihypertensive therapy [77]. This points to the need for effective OSA screening, diagnosis, and treatment to decrease cardiovascular risk [78, 79] besides improving the polysomnographic parameters and the quality of life [66, 80].

On the basis of all the above considerations, we feel it necessary for the scientific community to set up additional studies in order to expand the favorable extraglycemic effects of SGLT2is

to patients with OSA with and without diabetes, as depicted in Fig. 1.

ACKNOWLEDGEMENTS

Funding. No funding or sponsorship was received for this study or publication of this article.

Editorial Assistance. We are indebted to Dr. Paola Murano, General Manager of the Nefrocenter Research Network for the effective and continuous complimentary support to the manuscript preparation, and for editorial assistance.

Authorship. All named authors (Vincenzo Maria Monda, Sandro Gentile, Francesca Porcellati, Ersilia Satta, Alessandro Fucili, Marcello Monesi, and Felix Strollo) meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article taking responsibility for the integrity of the work as a whole, and gave their approval for this version to be published.

Authorship Contributions. Vincenzo Maria Monda wrote the manuscript, Felix Strollo and Sandro Gentile critically revised the text. Francesca Porcellati, Ersilia Satta, Alessandro Fucili, Marcello Monesi critically read and approved the paper. All authors contributed to bibliographic data acquisition, critically assessed the results, and approved the final text.

Disclosures. Vincenzo Maria Monda, Sandro Gentile, Francesca Porcellati, Ersilia Satta, Alessandro Fucili, Marcello Monesi, and Felice Strollo have no financial interests (no personal, financial, commercial, or academic conflicts of interest) to declare in relation to the present study.

Compliance with Ethics Guidelines. This study does not take into consideration data from directly observed diabetic patients, but is limited to analyzing data deriving from the literature.

Data Availability. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Open Access. This article is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If

material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

REFERENCES

1. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). *Circulation*. 2008;118(10):1080–111. <https://doi.org/10.1161/CIRCULATIONAHA.107.189375> (Erratum in *Circulation*. 2009 Mar 31;119(12):e380).
2. Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. *Circ Res*. 2019;124(11):1598–617. <https://doi.org/10.1161/CIRCRESAHA.119.313572>.
3. Trevisan L, Cautela J, Resseguier N, et al. Prevalence and characteristics of coronary artery disease in heart failure with preserved and mid-range ejection fractions: a systematic angiography approach. *Arch Cardiovasc Dis*. 2018;111(2):109–18. <https://doi.org/10.1016/j.acvd.2017.05.006>.
4. Mentz RJ, Kelly JP, von Lueder TG, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. *J Am Coll Cardiol*. 2014;64(21):2281–93. <https://doi.org/10.1016/j.jacc.2014.08.036>.
5. Unger ED, Dubin RF, Deo R, et al. Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. *Eur J Heart Fail*. 2016;18(1):103–12. <https://doi.org/10.1002/ejhf.445>.
6. Manolis AS, Manolis AA, Manolis TA, Melita H. Cardiac amyloidosis: an underdiagnosed/underappreciated disease. *Eur J Intern Med*. 2019;67:1–13. <https://doi.org/10.1016/j.ejim.2019.07.022>.
7. Sanderson JE, Fang F, Lu M, Ma CY, Wei YX. Obstructive sleep apnoea, intermittent hypoxia and

- heart failure with a preserved ejection fraction. *Heart*. 2021;107(3):190–4. <https://doi.org/10.1136/heartjnl-2020-317326>.
8. Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. *J Clin Sleep Med*. 2009;5(3):263–76.
 9. Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. *Chest*. 2014;146(5):1387–94. <https://doi.org/10.1378/chest.14-0970>.
 10. Shaw JE, Punjabi NM, Wilding JP, Alberti KG, Zimmet PZ, International Diabetes Federation Taskforce on Epidemiology and Prevention. Sleep-disordered breathing and type 2 diabetes: a report from the International Diabetes Federation Taskforce on Epidemiology and Prevention. *Diabetes Res Clin Pract*. 2008;81(1):2–12. <https://doi.org/10.1016/j.diabres.2008.04.025>.
 11. American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien: American Academy of Sleep Medicine; 2014.
 12. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline. *J Clin Sleep Med*. 2017;13(3):479–504. <https://doi.org/10.5664/jcsm.6506>.
 13. Malhotra RK, Kirsch DB, Kristo DA, et al. Polysomnography for obstructive sleep apnea should include arousal-based scoring: an American Academy of Sleep Medicine position statement. *J Clin Sleep Med*. 2018;14(7):1245–7. <https://doi.org/10.5664/jcsm.723>.
 14. Mannarino MR, Di Filippo F, Pirro M. Obstructive sleep apnea syndrome. *Eur J Intern Med*. 2012;23(7):586–93. <https://doi.org/10.1016/j.ejim.2012.05.013>.
 15. De Backer W. Obstructive sleep apnea/hypopnea syndrome. *Panminerva Med*. 2013;55(2):191–5.
 16. Lee W, Nagubadi S, Kryger MH, Mokhlesi B. Epidemiology of obstructive sleep apnea: a population-based perspective. *Expert Rev Respir Med*. 2008;2(3):349–64. <https://doi.org/10.1586/17476348.2.3.349>.
 17. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. *Sleep*. 1999;22(5):667–89.
 18. Wang T, Yu FC, Wei Q, et al. Prevalence and clinical characteristics of sleep-disordered breathing in patients with heart failure of different left ventricular ejection fractions. *Sleep Breath*. 2022. <https://doi.org/10.1007/s11325-022-02611-4>.
 19. Gupta N, Agrawal S, Goel AD, Ish P, Chakrabarti S, Suri JC. Profile of sleep disordered breathing in heart failure with preserved ejection fraction. *Monaldi Arch Chest Dis*. 2020. <https://doi.org/10.4081/monaldi.2020.1329>.
 20. Rech M, BarandiaránAizpurua A, van Empel V, van Bilsen M, Schroen B. Pathophysiological understanding of HFpEF: microRNAs as part of the puzzle. *Cardiovasc Res*. 2018;114:782–93. <https://doi.org/10.1093/cvr/cvy049>.
 21. Arnaud C, Bochaton T, Pépin JL, Belaidi E. Obstructive sleep apnoea and cardiovascular consequences: pathophysiological mechanisms. *Arch Cardiovasc Dis*. 2020;113(5):350–8. <https://doi.org/10.1016/j.acvd.2020.01.003>.
 22. Adamczak DM, Oduah MT, Kiebalo T, et al. Heart failure with preserved ejection fraction—a concise review. *Curr Cardiol Rep*. 2020;22(9):82. <https://doi.org/10.1007/s11886-020-01349-3>.
 23. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. *Eur Heart J*. 2006;27(19):2338–45. <https://doi.org/10.1093/eurheartj/ehl250>.
 24. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. *N Engl J Med*. 2008;359(23):2456–67. <https://doi.org/10.1056/NEJMoa0805450>.
 25. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. *Lancet*. 2003;362(9386):777–81. [https://doi.org/10.1016/S0140-6736\(03\)14285-7](https://doi.org/10.1016/S0140-6736(03)14285-7).
 26. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J*. 2005;26(3):215–25. <https://doi.org/10.1093/eurheartj/ehi115>.
 27. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. *N Engl J Med*. 2014;370(15):1383–92. <https://doi.org/10.1056/NEJMoa1313731>.
 28. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med*. 2014;371(11):993–1004. <https://doi.org/10.1056/NEJMoa1409077>.

-
29. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. *N Engl J Med*. 2019;381(17):1609–20. <https://doi.org/10.1056/NEJMoa1908655>.
 30. Fukuta H, Goto T, Wakami K, Ohte N. The effect of statins on mortality in heart failure with preserved ejection fraction: a meta-analysis of propensity score analyses. *Int J Cardiol*. 2016;214:301–6. <https://doi.org/10.1016/j.ijcard.2016.03.186>.
 31. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med*. 2021;385(16):1451–61. <https://doi.org/10.1056/NEJMoa2107038>.
 32. Monda VM, Porcellati F, Strollo F, et al. Possible preventative/rehabilitative role of gliflozins in OSA and T2DM. A systematic literature review-based hypothesis. *Adv Ther*. 2021;38(8):4195–214. <https://doi.org/10.1007/s12325-021-01791-x>.
 33. Lévy P, Naughton MT, Tamisier R, Cowie MR, Bradley TD. Sleep apnoea and heart failure. *Eur Respir J*. 2022;59(5):2101640. <https://doi.org/10.1183/13993003.01640-2021>.
 34. Abdullah A, Eigbire G, Salama A, Wahab A, Nadkarni N, Alweis R. Relation of obstructive sleep apnea to risk of hospitalization in patients with heart failure and preserved ejection fraction from the national inpatient sample. *Am J Cardiol*. 2018;122(4):612–5. <https://doi.org/10.1016/j.amjcard.2018.04.052>.
 35. Lam CSP, Arnott C, Beale AL, et al. Sex differences in heart failure. *Eur Heart J*. 2019;40(47):3859–3868c. <https://doi.org/10.1093/eurheartj/ehz835>.
 36. Lebek S, Hegner P, Tafelmeier M, et al. Female patients with sleep-disordered breathing display more frequently heart failure with preserved ejection fraction. *Front Med (Lausanne)*. 2021;8:675987. <https://doi.org/10.3389/fmed.2021.675987>.
 37. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med*. 2019;380(24):2295–306. <https://doi.org/10.1056/NEJMoa1811744>.
 38. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. *N Engl J Med*. 2020;383(15):1436–46. <https://doi.org/10.1056/NEJMoa2024816>.
 39. Yun JS, Ahn YB, Song KH, et al. The association between abnormal heart rate variability and new onset of chronic kidney disease in patients with type 2 diabetes: a ten-year follow-up study. *Diabetes Res Clin Pract*. 2015;108(1):31–7. <https://doi.org/10.1016/j.diabres.2015.01.031>.
 40. Tahrani AA, Dubb K, Raymond NT, et al. Cardiac autonomic neuropathy predicts renal function decline in patients with type 2 diabetes: a cohort study. *Diabetologia*. 2014;57(6):1249–56. <https://doi.org/10.1007/s00125-014-3211-2>.
 41. Faulx MD, Storfer-Isser A, Kirchner HL, Jenny NS, Tracy RP, Redline S. Obstructive sleep apnea is associated with increased urinary albumin excretion. *Sleep*. 2007;30(7):923–9. <https://doi.org/10.1093/sleep/30.7.923>.
 42. Abuyassin B, Sharma K, Ayas NT, Laher I. Obstructive sleep apnea and kidney disease: a potential bidirectional relationship? *J Clin Sleep Med*. 2015;11(8):915–24. <https://doi.org/10.5664/jcsm.4946>.
 43. Turek NF, Ricardo AC, Lash JP. Sleep disturbances as nontraditional risk factors for development and progression of CKD: review of the evidence. *Am J Kidney Dis*. 2012;60(5):823–33. <https://doi.org/10.1053/j.ajkd.2012.04.027>.
 44. Siwasaranond N, Nimitphong H, Manodpitipong A, et al. Relationship between diabetes-related complications and obstructive sleep apnea in type 2 diabetes. *J Diabetes Res*. 2018;2018:9269170. <https://doi.org/10.1155/2018/9269170>.
 45. Lin CH, Perger E, Lyons OD. Obstructive sleep apnea and chronic kidney disease. *Curr Opin Pulm Med*. 2018;24(6):549–54. <https://doi.org/10.1097/MCP.0000000000000525>.
 46. Choi HS, Kim HY, Han KD, et al. Obstructive sleep apnea as a risk factor for incident end stage renal disease: a nationwide population-based cohort study from Korea. *Clin Exp Nephrol*. 2019;23(12):1391–7. <https://doi.org/10.1007/s10157-019-01779-6>.
 47. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. *J Clin Endocrinol Metab*. 2012;97(3):1020–31. <https://doi.org/10.1210/jc.2011-2260>.
 48. Bolinder J, Ljunggren Ö, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. *Diabetes Obes Metab*. 2014;16(2):159–69. <https://doi.org/10.1111/dom.12189>.
-

49. ČertíkováChábová V, Zakiyanov O. Sodium glucose cotransporter-2 inhibitors: spotlight on favorable effects on clinical outcomes beyond diabetes. *Int J Mol Sci.* 2022;23(5):2812. <https://doi.org/10.3390/ijms23052812>.
50. Yokono M, Takasu T, Hayashizaki Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. *Eur J Pharmacol.* 2014;15(727):66–74. <https://doi.org/10.1016/j.ejphar.2014.01.040>.
51. Liang Y, Arakawa K, Ueta K, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. *PLoS One.* 2012;7(2):e30555. <https://doi.org/10.1371/journal.pone.0030555>.
52. Suzuki M, Takeda M, Kito A, et al. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. *Nutr Diabetes.* 2014;4:e125. <https://doi.org/10.1038/nutd.2014.20>.
53. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium–glucose cotransporter 2 inhibition in type 2 diabetic patients. *J Clin Investig.* 2014;124(2):499–508. <https://doi.org/10.1172/JCI72227>.
54. Itani T, Ishihara T. Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study. *Obes Sci Pract.* 2018;4(5):477–82. <https://doi.org/10.1002/osp4.294>.
55. Raj H, Durgia H, Palui R, et al. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: a systematic review. *World J Diabetes.* 2019;10(2):114–32. <https://doi.org/10.4239/wjcd.v10.i2.114>.
56. Choi DH, Jung CH, Mok JO, Kim CH, Kang SK, Kim BY. Effect of dapagliflozin on alanine aminotransferase improvement in type 2 diabetes mellitus with non-alcoholic fatty liver disease. *Endocrinol Metab (Seoul).* 2018;33(3):387–94. <https://doi.org/10.3803/EnM.2018.33.3.387>.
57. Shimizu M, Suzuki K, Kato K, et al. Evaluation of the effects of dapagliflozin, a sodium–glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. *Diabetes Obes Metab.* 2019;21(2):285–92. <https://doi.org/10.1111/dom.13520>.
58. Omori K, Nakamura A, Miyoshi H, et al. Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice. *Metabolism.* 2019;98:27–36. <https://doi.org/10.1016/j.metabol.2019.06.006>.
59. Yagi S, Hirata Y, Ise T, et al. Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. *Diabetol Metab Syndr.* 2017;4(9):78. <https://doi.org/10.1186/s13098-017-0275-4>.
60. Shimabukuro M, Hirata Y, Tabata M, et al. Epicardial adipose tissue volume and adipocytokine imbalance are strongly linked to human coronary atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2013;33(5):1077–84. <https://doi.org/10.1161/ATVBAHA.112.300829>.
61. Mahabadi AA, Lehmann N, Kälsch H, et al. Association of epicardial adipose tissue with progression of coronary artery calcification is more pronounced in the early phase of atherosclerosis: results from the Heinz Nixdorf recall study. *JACC Cardiovasc Imaging.* 2014;7(9):909–16. <https://doi.org/10.1016/j.jcmg.2014.07.002>.
62. Scheen AJ. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications. *Diabetes Metab.* 2019;45(3):213–23. <https://doi.org/10.1016/j.diabet.2019.01.008>.
63. Neeland IJ, Eliasson B, Kasai T, et al. The impact of empagliflozin on obstructive sleep apnea and cardiovascular and renal outcomes: an exploratory analysis of the EMPA-REG OUTCOME trial. *Diabetes Care.* 2020;43(12):3007–15. <https://doi.org/10.2337/dc20-1096>.
64. Mesarwi OA, Loomba R, Malhotra A. Obstructive sleep apnea, hypoxia, and nonalcoholic fatty liver disease. *Am J Respir Crit Care Med.* 2019;199(7):830–41. <https://doi.org/10.1164/rccm.201806-1109TR>.
65. Mechler C, Ledoux S, Harnois F, Coffin B. Relationship between obstructive sleep apnea and liver abnormalities in morbidly obese patients: a prospective study. *Obes Surg.* 2007;17(4):478–85. <https://doi.org/10.1007/s11695-007-9085-3>.
66. Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. *J Am Coll Cardiol.* 2013;62(7):569–76. <https://doi.org/10.1016/j.jacc.2013.05.045>.
67. Salah HM, Pandey A, Soloveva A, et al. Relationship of nonalcoholic fatty liver disease and heart failure with preserved ejection fraction. *JACC Basic Transl Sci.* 2021;6(11):918–32. <https://doi.org/10.1016/j.jacbts.2021.07.010>.
68. Packer M. Atrial fibrillation and heart failure with preserved ejection fraction in patients with

- nonalcoholic fatty liver disease. *Am J Med.* 2020;133(2):170–7. <https://doi.org/10.1016/j.amjmed.2019.09.002>.
69. Miller A, McNamara J, Hummel SL, Konerman MC, Tincopa MA. Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction. *Sci Rep.* 2020;10(1):12440. <https://doi.org/10.1038/s41598-020-69013-y>.
70. Avogaro A, Fadini GP. Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin. *Diabetes Obes Metab.* 2018;20(6):1367–8. <https://doi.org/10.1111/dom.13234>.
71. Packer M. Do sodium–glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. *Diabetes Obes Metab.* 2018;20(6):1361–6. <https://doi.org/10.1111/dom.13229>.
72. Pan W, Kastin AJ. Leptin: a biomarker for sleep disorders? *Sleep Med Rev.* 2014;18(3):283–90. <https://doi.org/10.1016/j.smrv.2013.07.003>.
73. Berger S, Polotsky VY. Leptin and leptin resistance in the pathogenesis of obstructive sleep apnea: a possible link to oxidative stress and cardiovascular complications. *Oxid Med Cell Longev.* 2018;2018:5137947. <https://doi.org/10.1155/2018/5137947>.
74. Wu P, Wen W, Li J, et al. Systematic review and meta-analysis of randomized controlled trials on the effect of SGLT2 inhibitor on blood leptin and adiponectin level in patients with type 2 diabetes. *Horm Metab Res.* 2019;51(8):487–94. <https://doi.org/10.1055/a-0958-2441>.
75. Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation.* 2021;144(3):e56–67. <https://doi.org/10.1161/CIR.0000000000000988>.
76. Baillieux S, Dekkers M, Brill AK, et al. Sleep apnoea and ischaemic stroke: current knowledge and future directions. *Lancet Neurol.* 2022;21(1):78–88. [https://doi.org/10.1016/S1474-4422\(21\)00321-5](https://doi.org/10.1016/S1474-4422(21)00321-5).
77. Muxfeldt ES, Margallo VS, Guimarães GM, Salles GF. Prevalence and associated factors of obstructive sleep apnea in patients with resistant hypertension. *Am J Hypertens.* 2014;27(8):1069–78. <https://doi.org/10.1093/ajh/hpu023>.
78. Salman LA, Shulman R, Cohen JB. Obstructive sleep apnea, hypertension, and cardiovascular risk: epidemiology, pathophysiology, and management. *Curr Cardiol Rep.* 2020;22(2):6. <https://doi.org/10.1007/s11886-020-1257-y>.
79. Wang Y, Shou X, Wu Y, et al. Relationships between obstructive sleep apnea and cardiovascular disease: a bibliometric analysis (2010–2021). *Med Sci Monit.* 2022;28: e933448. <https://doi.org/10.12659/MSM.933448>.
80. Tang Y, Sun Q, Bai XY, Zhou YF, Zhou QL, Zhang M. Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study. *Nutr Diabetes.* 2019;9(1):32. <https://doi.org/10.1038/s41387-019-0098-5>.